etodolac has been researched along with fluorouracil in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Hirakawa, K; Matsunaga, N; Yamada, N | 1 |
| Hirakawa, K; Matsunaga, N; Nishiguchi, Y; Nishino, H; Ohira, M; Seki, S; Tachimori, A; Yamada, N | 1 |
| Chen, WS; Lin, JK; Liu, JH; Liu, JM | 1 |
| Adachi, M; Bhayani, MK; Hasegawa, Y; Ijichi, K; Kioi, M; Lai, SY; Mitsudo, K; Murata, S; Ogawa, T; Tohnai, I; Torigoe, S | 1 |
| Bollareddy, SR; Dasari, D; Dhar, A; Krishna, V; Roy, G; Venuganti, VVK | 1 |
1 review(s) available for etodolac and fluorouracil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for etodolac and fluorouracil
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
[Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitors for liver metastasis of colon cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Cyclooxygenase Inhibitors; Depression, Chemical; Disease Models, Animal; Etodolac; Fluorouracil; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Tumor Cells, Cultured | 2003 |
Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Etodolac; Female; Fluorouracil; Humans; Isoenzymes; Liver Neoplasms; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Prostaglandin-Endoperoxide Synthases; Xenograft Model Antitumor Assays | 2004 |
Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Etodolac; Fluorouracil; HT29 Cells; Humans; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Topoisomerase I Inhibitors | 2004 |
Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cyclooxygenase 2; Down-Regulation; Enzyme Inhibitors; Etodolac; Fluorouracil; Head and Neck Neoplasms; Humans; Interleukin-1beta; Thymidylate Synthase | 2011 |
Transfersome Hydrogel Containing 5-Fluorouracil and Etodolac Combination for Synergistic Oral Cancer Treatment.
Topics: Administration, Cutaneous; Animals; Drug Carriers; Etodolac; Fluorouracil; Hydrogels; Liposomes; Mouth Neoplasms; Particle Size; Swine | 2022 |